{
  "id": "134ebe6596eea0c2",
  "title": "Innovent Announces IBI3003 ( GPRC5D / BCMA / CD3 Trispecific Antibody ) Receives Fast Track Designation from the U . S . FDA for Relapsed or Refractory Multiple Myeloma",
  "description": "20260127T011500Z",
  "content": "",
  "source": "manilatimes.net",
  "source_url": "https://www.manilatimes.net/2026/01/27/tmt-newswire/pr-newswire/innovent-announces-ibi3003-gprc5dbcmacd3-trispecific-antibody-receives-fast-track-designation-from-the-us-fda-for-relapsed-or-refractory-multiple-myeloma/2265621",
  "published_at": "20260127T011500Z",
  "fetched_at": "2026-01-28T00:24:25.269376+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda"
  ],
  "location": "Philippines",
  "raw_data": {
    "url": "https://www.manilatimes.net/2026/01/27/tmt-newswire/pr-newswire/innovent-announces-ibi3003-gprc5dbcmacd3-trispecific-antibody-receives-fast-track-designation-from-the-us-fda-for-relapsed-or-refractory-multiple-myeloma/2265621",
    "url_mobile": "https://www.manilatimes.net/2026/01/27/tmt-newswire/pr-newswire/innovent-announces-ibi3003-gprc5dbcmacd3-trispecific-antibody-receives-fast-track-designation-from-the-us-fda-for-relapsed-or-refractory-multiple-myeloma/2265621/amp",
    "title": "Innovent Announces IBI3003 ( GPRC5D / BCMA / CD3 Trispecific Antibody ) Receives Fast Track Designation from the U . S . FDA for Relapsed or Refractory Multiple Myeloma",
    "seendate": "20260127T011500Z",
    "socialimage": "https://www.manilatimes.net/theme_manilatimes/images/TMT_1920x1008.jpg",
    "domain": "manilatimes.net",
    "language": "English",
    "sourcecountry": "Philippines"
  }
}